Skip to main content
    K

    Korro Bio, Inc. (KRRO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $12.71
    -0.90 (-6.61%)

    Market Cap: $186.81M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Korro Bio, Inc. (KRRO) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Korro Bio are Rocket Pharmaceuticals (RCKT), ProQR Therapeutics BV (PRQR) and Precision BioSciences (DTIL). By market cap, Korro Bio ranks 10th of the 13 companies on this page; Editas Medicine (EDIT) is the largest at $334.92M.

    Peer Comparison

    KRRO's ROIC of -82.8% is below the peer median of -40.3%, and its revenue growth of -43.1% is below the median of 3.4%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Korro Bio (KRRO)$186.81MN/A175.8x0.0%-82.8%-43.1%0.00%
    Rocket Pharmaceuticals Inc (RCKT)$256.82MN/AN/A0.0%-2.3%0.0%0.00%
    ProQR Therapeutics BV (PRQR)$199.28MN/A6.1x-228.2%N/A120.4%0.00%
    Precision BioSciences Inc (DTIL)$288.76MN/A4.4x-85.6%-38.3%37272.0%0.00%
    Keros Therapeutics Inc (KROS)$202.13MN/A4.9x-151.4%N/A180.5%0.00%
    Upstream Bio, Inc. (UPB)$152.38MN/A41.0x0.0%N/A-42.2%0.00%
    Palisade Bio Inc (PALI)$201.01MN/A436.8x0.0%N/A0.0%0.00%
    Codexis Inc (CDXS)$127.13MN/AN/A-21.8%N/A124.0%0.00%
    SAB Biotherapeutics Inc (SABS)$266.66MN/AN/A0.0%N/A-62.4%0.00%
    Editas Medicine Inc (EDIT)$334.92MN/A5.6x-145.0%-42.3%37.4%0.00%
    Arcturus Therapeutics Holdings Inc (ARCT)$240.96MN/A7.7x-285.9%N/A6.7%0.00%
    Immuneering Corp (IMRX)$240.27MN/AN/A0.0%N/A-99.8%0.00%
    MacroGenics Inc (MGNX)$140.60MN/A1.2x-36.6%-108.7%-64.8%0.00%
    Peer median$221.20MN/A5.8x-29.2%-40.3%3.4%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Korro Bio, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Rocket Pharmaceuticals Inc (RCKT)
    Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases.
    RCKT competitors
    ProQR Therapeutics BV (PRQR)
    ProQR Therapeutics NV, a biopharmaceutical company, is dedicated to the discovery and development of RNA-based therapies for the treatment of genetic disorders.
    PRQR competitors
    Precision BioSciences Inc (DTIL)
    Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States.
    DTIL competitors
    Keros Therapeutics Inc (KROS)
    Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery...
    KROS competitors
    Upstream Bio, Inc. (UPB)
    Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders.
    UPB competitors
    Palisade Bio Inc (PALI)
    Leading BioSciences, Inc. develops therapies to improve human health through therapeutic protection of the gastrointestinal mucosal barrier.
    PALI competitors
    Codexis Inc (CDXS)
    Codexis, Inc. discovers, develops and sells biocatalysts. The company is headquartered in Redwood City, California.
    CDXS competitors
    SAB Biotherapeutics Inc (SABS)
    SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology.
    SABS competitors
    Editas Medicine Inc (EDIT)
    Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases.
    EDIT competitors
    Arcturus Therapeutics Holdings Inc (ARCT)
    Arcturus Therapeutics Holdings Inc., an RNA drug company, focuses on the treatment of liver and respiratory diseases.
    ARCT competitors
    Immuneering Corp (IMRX)
    Immuneering Corp (IMRX) is a cutting-edge biotechnology firm dedicated to advancing targeted therapeutics for cancer and other critical illnesses through its...
    IMRX competitors
    MacroGenics Inc (MGNX)
    MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States.
    MGNX competitors

    Frequently Asked Questions About KRRO

    Who are Korro Bio's main competitors?

    The companies most similar to Korro Bio include Rocket Pharmaceuticals (RCKT), ProQR Therapeutics BV (PRQR), Precision BioSciences (DTIL), Keros Therapeutics (KROS) and Upstream Bio (UPB), listed from the closest match.

    Who is Korro Bio's biggest competitor?

    Editas Medicine (EDIT) is the largest of the similar companies at $334.92M; Rocket Pharmaceuticals (RCKT) is the closest match by business profile, size, sector and industry.

    How does KRRO stock compare with its competitors?

    KRRO's P/S is 175.8x against a peer median of 5.8x; its net margin is 0.0% against a peer median of -29.2%.

    Which of Korro Bio's competitors pays a higher dividend?

    Korro Bio pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Korro Bio bigger than its competitors?

    No. Korro Bio is 10th by market cap among the 13 companies on this page; the largest is Editas Medicine (EDIT) at $334.92M.